Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers

Cancer Investigation

Volumn 23, Issue 8, 2005, Pages 653-659

  Kreuter, Alexander ^a   Rasokat, Heinrich ^b   Klouche, Mariam ^c   Esser, Stefan ^d   Bader, Armin ^a   Gambichler, Thilo ^a,e   Altmeyer, Peter ^a   Brockmeyer, Norbert H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Old Church Hospital ^*

^e OLDCHURCH HOSPITAL   (United Kingdom)

Author keywords

Classic Kaposi's Sarcoma; Low Dose Recombinant Interferon Alfa 2a; Pegylated Liposomal Doxorubicin

Indexed keywords

DOXORUBICIN; ONDANSETRON; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FEVER; FISHER EXACT TEST; FLU LIKE SYNDROME; FOLLOW UP; GERMANY; HEADACHE; HISTOLOGY; HUMAN; KAPOSI SARCOMA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STUDENT T TEST; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; GERMANY; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI;

EID: 29944444439     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500358259     Document Type: Article

References (31)

1. Chor, P.J.; Santa Cruz, D.J. Kaposi's sarcoma: a clinicopathologic review and differential diagnosis. J. Cutan. Pathol. 1992, 19, 6-20.
2. Tur. E.; Brenner, S. Treatment of Kaposi's sarcoma. Arch. Dermatol. 1996, 132, 285-290.
3. Tur, E.; Brenner, S.; Michalevicz R. Low dose recombinant interferon alfa treatment for classic Kaposi's sarcoma. Arch. Dermatol. 1993, 129, 1297-1300.
4. Shimizu, S.; Tanaka, M.; Niizeki, H.; Miyakawa, S.; Ishiko, A.; Shimizu, H. Classic (non-AIDS-related) Kaposi's sarcoma in a Japanese patient, successfully treated with alpha-2b-interferon. Br. J. Dermatol. 1995, 133, 329-347.
5. Killeen, R.B.; De Wilton Marsh, R. Alfa-interferon for Kaposi's sarcoma in HIV-negative, non-homosexual man. Lancet 1991, 337, 309-310.
6. Miralles, E.S.; Perez, B.; Nunez, M.; Ledo, A. Low-dose recombinant interferon alfa-2a treatment for classic Kaposi's sarcoma. Arch. Dermatol. 1993, 129, 1297-1300.
7. Rybojad. M.; Borradori, L.; Verola, O.; Zeller, J.; Puissant, A.; Morel, P. Non-AIDS-associated Kaposi's sarcoma (classic and endenic African types): treatment with low doses of recombinant interferon-alpha. J. Invest. Dermatol. 1990, 95, 176-179.
8. Wagner, D.; Kern, W.V.; Kern, P. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences. Clin. Invest. 1994, 72, 417-423.
9. Bogner, J.R.; Kronawitter, U.; Rolinski, B.; Truebenbach, K.; Goebel, F.D. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acq. Immune. Def. Syndr. 1994, 7, 463-468.
10. Krown, S.E.; Metroka, C.; Wernz, J.C. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 1989, 7, 1201-1207.
11. Costa da Cunha, C.S.; Lebbe, C.; Rybojad, M.; Agbalika, F.; Ferchal, F.; Rabian, C.; Vignon-Pennamen, M.D.; Calvo, F.; Morel, P. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch. Dermatol. 1996, 132, 285-290.
12. Chang, Y.; Cesarman, E.; Pessin, M.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266, 1865-1869.
13. Moore, P.S.; Chang, Y. Kaposi's sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am. J. Epidemiol. 1998, 147, 217-221.
14. Lii, J.J.; Huang, Y.Q.; Cockerell, C.J.; Friedman-Kien, A.E. Localisation of human herpes-like virus type 8 in vascular endothelial cells and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ hybridisation. Am. J. Pathol. 1996, 148, 1741-1748.
15. Stürzl, M.; Ensoli, B. Big but weak: how many pathogenic genes does human herpesvirus-8 need to cause Kaposi's sarcoma? Int. J. Oncol. 1999, 14, 287-289.
16. Boshoff, C.; Schulz, T.F.; Kennedy, M.M.; et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat. Med. 1995, 1, 1274-1278.
17. Caputo, R.; Gianotti, R.; Grimalt, R. Soft fibroma-like lesions on the legs of a patient with Kaposi's sarcoma and lymphedema. Am. J. Dermatopathol. 1991, 13, 493-496.
18. Klouche, M.; Brockmeyer, N.; Knabbe, C.; Rose-John, S. Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. AIDS 2002, 16, F9-18.
19. Gill, P.S.; Rarick, M.; McCutchan, J.A. Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomised trial. Am. J. Med. 1991, 90, 427-133.
20. Northfelt, D.W. Treatment of Kaposi's sarcoma: Current guidelines and future perspectives. Drugs. 1994, 48, 569-582.
21. Papahadjopoulos, D.; Allen, T.M.; Gabzon, A.; et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumour therapeutic efficacy. Proc. Natl. Acad. Sci. USA 1991, 88, 11460-11464.
22. Ockenfels, H.M.; Brockmeyer, N.H.; Hengge, U.R. et al. Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicin? J. Eur. Acad. Derm. Venereol. 1996, 6, 71-75.
23. Goebel, F.D.; Goldstein, D.; Goos, M.; Jablonowski, H.; Stewart, J.S. for the International SL-DOX Study Group. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer 1996, 73, 989-994.
24. Northfelt, D.W.; Dezube, B.J.; Thommes, J.A. et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997, 15, 653-659.
25. Brockmeyer, N.H.; Barthel, B. Clinical manifestations and therapies of AIDS associated tumors. Eur. J. Med. Res. 1998, 3, 127-147.
26. Nunez, M.; Saballs, P.; Valencia, M.E. et al. Caelyx/KS Spanish Study Group. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV. Clin. Trials. 2001, 2, 429-437.
27. Gottlieb, J.J.; Washenik, K.; Chachoua, A.; Friedman-Kien, A. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet. 1997, 350, 1363-1364.
28. Rozenbaum, W.; Gharakhanian, S.; Navarrete, M.S.; De Sahb, R.; Cardon, B.; Rouzioux, C. Long-term follow-up of 120 patients with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a. J. Invest. Dermatol. 1990, 95, 161-165.
29. Krown, S.E. AIDS-associated Kaposi's sarcoma: pathogenesis, clinical course and treatment. AIDS 1988, 2, 71-80.
30. Real, F.X.; Krown, S.E.; Oettgen, H.F. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leucocyte A interferon. J. Clin. Oncol. 1986, 4, 544-551.
31. Tur, E.; Brenner, S. Classic Kaposi's sarcoma: low-dose interferon alfa treatment. Dermatology 1998, 197, 37-42.